MedTrace Logo

Pain Study to See if Ultram ER Will Provide Relief to Subjects Whose Pain is Not Well Controlled by Narcotics

NCT00505531 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 7

Last updated 2020-07-22

No results posted yet for this study

Summary

The Massachusetts General Hospital Center for Translational Pain Research is conducting a research study to see if Ultram ER, an FDA-approved pain medication, would be helpful in providing pain relief in subjects whose chronic pain is not well controlled on narcotic pain medicine.

Conditions

Interventions

DRUG

Tramadol Extended Release Oral Capsule

Tramadol ER- up to either 200 mg or 300 mg based on randomization

DRUG

Benadryl

Placebo group will take up to 25 mg of Benadryl

Sponsors & Collaborators

  • Ortho-McNeil, Inc.

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Jianren Mao, M.D. · Massachusetts General Hospital

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00505531 on ClinicalTrials.gov